Literature DB >> 27749511

Early Noninvasive Neurally Adjusted Ventilatory Assist Versus Noninvasive Flow-Triggered Pressure Support Ventilation in Pediatric Acute Respiratory Failure: A Physiologic Randomized Controlled Trial.

Giovanna Chidini1, Daniele De Luca, Giorgio Conti, Paolo Pelosi, Stefano Nava, Edoardo Calderini.   

Abstract

OBJECTIVE: Neurally adjusted ventilatory assist has been shown to improve patient-ventilator interaction in children with acute respiratory failure. Objective of this study was to compare the effect of noninvasive neurally adjusted ventilatory assist versus noninvasive flow-triggered pressure support on patient-ventilator interaction in children with acute respiratory failure, when delivered as a first-line respiratory support.
DESIGN: Prospective randomized crossover physiologic study.
SETTING: Pediatric six-bed third-level PICU. PATIENTS: Eighteen children with acute respiratory failure needing noninvasive ventilation were enrolled at PICU admission.
INTERVENTIONS: Enrolled children were allocated to receive two 60-minutes noninvasive flow-triggered pressure support and noninvasive neurally adjusted ventilatory assist trials in a crossover randomized sequence.
MEASUREMENTS AND MAIN RESULTS: Primary endpoint was the asynchrony index. Parameters describing patient-ventilator interaction and gas exchange were also considered as secondary endpoints. Noninvasive neurally adjusted ventilatory assist compared to noninvasive flow-triggered pressure support: 1) reduced asynchrony index (p = 0.001) and the number of asynchronies per minute for each type of asynchrony; 2) it increased the neuroventilatory efficiency index (p = 0.001), suggesting better neuroventilatory coupling; 3) reduced inspiratory and expiratory delay times (p = 0.001) as well as lower peak and mean airway pressure (p = 0.006 and p = 0.038, respectively); 4) lowered oxygenation index (p = 0.043). No adverse event was reported.
CONCLUSIONS: In children with mild early acute respiratory failure, noninvasive neurally adjusted ventilatory assist was feasible and safe. Noninvasive neurally adjusted ventilatory assist compared to noninvasive flow-triggered pressure support improved patient-ventilator interaction.

Entities:  

Mesh:

Year:  2016        PMID: 27749511     DOI: 10.1097/PCC.0000000000000947

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

1.  Feasibility of neurally synchronized and proportional negative pressure ventilation in a small animal model.

Authors:  Daijiro Takahashi; Ling Liu; Christer Sinderby; Jennifer Beck
Journal:  Physiol Rep       Date:  2020-07

2.  Pressure Support Ventilation (PSV) versus Neurally Adjusted Ventilatory Assist (NAVA) in difficult to wean pediatric ARDS patients: a physiologic crossover study.

Authors:  Giorgia Spinazzola; Roberta Costa; Daniele De Luca; Giovanna Chidini; Giuliano Ferrone; Marco Piastra; Giorgio Conti
Journal:  BMC Pediatr       Date:  2020-07-07       Impact factor: 2.125

3.  Severe diaphragmatic dysfunction with preserved activity of accessory respiratory muscles in a critically ill child: a case report of failure of neurally adjusted ventilatory assist (NAVA) and successful support with pressure support ventilation (PSV).

Authors:  Thomas Langer; Serena Baio; Giovanna Chidini; Tiziana Marchesi; Giacomo Grasselli; Antonio Pesenti; Edoardo Calderini
Journal:  BMC Pediatr       Date:  2019-05-17       Impact factor: 2.125

4.  Dexmedetomidine is effective and safe during NIV in infants and young children with acute respiratory failure.

Authors:  M Piastra; A Pizza; S Gaddi; E Luca; O Genovese; E Picconi; D De Luca; G Conti
Journal:  BMC Pediatr       Date:  2018-08-25       Impact factor: 2.125

5.  Neurally Adjusted Ventilatory Assist vs. Conventional Mechanical Ventilation in Adults and Children With Acute Respiratory Failure: A Systematic Review and Meta-Analysis.

Authors:  Mengfan Wu; Xueyan Yuan; Ling Liu; Yi Yang
Journal:  Front Med (Lausanne)       Date:  2022-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.